argenex (NASDAQ:ARGX) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of argenex (NASDAQ:ARGX) from a buy rating to a hold rating in a research report report published on Sunday,Wall Street Zen reports.

A number of other research firms have also recently commented on ARGX. Citigroup lifted their price objective on argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Barclays restated a “buy” rating on shares of argenex in a report on Monday, September 7th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of argenex in a research note on Friday, September 25th. Wedbush lowered their price target on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating for the company in a report on Thursday, October 8th. Finally, Guggenheim cut their price objective on shares of argenex from $1,185.00 to $1,120.00 and set a “buy” rating for the company in a research report on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,145.00.

argenex Price Performance

argenex stock opened at $882.48 on Friday. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The stock has a fifty day moving average of $951.24 and a two-hundred day moving average of $853.30.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.44 by $0.36. The company had revenue of $1.75 billion during the quarter. Research analysts predict that argenex will post 26.10 earnings per share for the current year.

Hedge Funds Weigh In On argenex

Several large investors have recently added to or reduced their stakes in ARGX. Eastern Bank acquired a new stake in argenex in the 2nd quarter worth about $32,000. Whipplewood Advisors LLC purchased a new position in shares of argenex during the 1st quarter worth about $28,000. Axiom Investment Management LLC purchased a new position in shares of argenex during the 1st quarter worth about $50,000. Mather Group LLC. lifted its holdings in shares of argenex by 19.1% during the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after acquiring an additional 13 shares during the period. Finally, WPG Advisers LLC boosted its position in shares of argenex by 17.8% in the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after acquiring an additional 13 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Citigroup lowered its price target to $1,232 from $1,301 but maintained a Buy rating. The revised target still implies substantial upside from the recent trading level, signaling continued confidence in argenx’s growth outlook. Citigroup price-target update
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $27.76 from $26.27 and increased its Q4 2026 estimate to $7.13 from $6.93. The firm reiterated its Buy rating and $1,202 price objective. HC Wainwright earnings estimates
• Neutral Sentiment: Reported short interest was zero shares as of October 26, producing a 0.0-day short-interest ratio. While this suggests little disclosed short-selling pressure, the figure provides limited insight into near-term trading direction. argenx short-interest report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of argenx investors. The announcement could weigh on sentiment by raising the prospect of litigation, although it did not disclose specific findings or allegations. Pomerantz investor investigation
• Negative Sentiment: HC Wainwright reduced its Q1 2027 EPS forecast to $6.54 from $7.57 and cut its FY2027 estimate to $33.52 from $34.82. These reductions indicate softer longer-term earnings expectations, despite the firm’s continued Buy rating. HC Wainwright earnings estimate changes

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.